Peter Smith

Company: Astra Zeneca

Job title: Director - New Modalities Chemistry

Seminars:

Looking at Oligonucleotide DS CMC Capabilities 2:15 pm

Early-phase oligonucleotide CMC challenges: achieving phase-appropriate controls, quality & regulatory oversight whilst maintaining agility against project delivery requirements Evolution of AstraZeneca's approach to oligonucleotide portfolio expansion drives new ways of working The expansion and uplift of internal capabilities enables the future growth of oligonucleotide DS CMC development within AstraZenecaRead more

day: Day Two

Panel Discussion: Outlining Current Industry Trends in Oligonucleotide Development 9:00 am

• Discussing the movement away from the development of oligonucleotides for rare diseases • Capitalizing on opportunities and changes we anticipate in the future and newer complex oligos coming into pipelines • Outlining challenges of COGs, scale, impurity characterization and qualificationRead more

day: Day One